Article Text

PDF
Targeted therapies in systemic lupus erythematosus: successes, failures and future
  1. Bevra H Hahn
  1. Correspondence to Dr Bevra H Hahn, Division of Rheumatology, David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32-59, Los Angeles, CA 90095, USA; bhahn{at}mednet.ucla.edu

Abstract

Purpose The author's goal is to review recent phase III clinical trials in patients with systemic lupus erythematosus (SLE), with emphasis on outcomes and on mechanisms by which the experimental drugs/biological agents suppress autoimmunity.

Methods Prospective, randomised, controlled clinical trials in SLE published in the past 3 years identified in a PubMed search were reviewed, as well as abstracts describing similar but currently unpublished clinical trials presented at international meetings 2008–10.

Conclusions Two interventions have been proved in large multicentre prospective trials to be useful in the management of SLE: mycophenolate mofetil (equivalent to cyclophosphamide with a similar safety profile) and anti-BLyS (Benlysta), which was superior to placebo when added to background immunosuppression and did not appear to increase toxicity. The anti-BLyS trial outcome measure was an anchored composite index that required reduction of disease activity measure by the systemic lupus erythematosus disease activity index. Other trials that failed or the results of which are pending are also discussed.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.